Long‑term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report
Neuroendocrine neoplasms of the pancreas (pNENs) are rare. In February 2021, a 54-year-old woman was diagnosed with pNEN and multiple metastases within the liver. The patient, diagnosed with grade G2 neuroendocrine neoplasm (T4N0M1), underwent an ultrasonography-guided liver biopsy and radiofrequenc...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2025-01, Vol.29 (1), p.49, Article 49 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 49 |
| container_title | Oncology letters |
| container_volume | 29 |
| creator | Zhao, Lei Cheng, Xin Zhao, Hongbin Zhao, Haifei Di, Wenyu Mei, Zhihong |
| description | Neuroendocrine neoplasms of the pancreas (pNENs) are rare. In February 2021, a 54-year-old woman was diagnosed with pNEN and multiple metastases within the liver. The patient, diagnosed with grade G2 neuroendocrine neoplasm (T4N0M1), underwent an ultrasonography-guided liver biopsy and radiofrequency ablation. After receiving Sandostatin LAR in April 2021, side effects led to its discontinuation after seven cycles. Following two sessions of radiofrequency ablation, the patient's condition was stable. However, disease progression was noted in September 2023, resulting in hemodialysis and closed peritoneal drainage. Surufatinib was administered, stabilizing the tumor by November 2023. The patient underwent transarterial chemoembolization due to a large tumor burden, with subsequent MRCP showing stability from diagnosis in February 2021 to June 2024. The present case report highlights the role of tailored treatment strategies considering patient comorbidities and tumor biology, and the significance of secondary puncture biopsy, which, despite not being pursued by the patient in the present study due to the associated risks, may provide survival benefits for patients with advanced or metastatic pNEN. |
| doi_str_mv | 10.3892/ol.2024.14795 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11574579</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3134600273</sourcerecordid><originalsourceid>FETCH-LOGICAL-c302t-28fd19b506caf21433ec8d2600ce4c3ddf6da16fd0df7e8c6e19626cabbbf5e33</originalsourceid><addsrcrecordid>eNpVUU1v1TAQtFARrUqPXJElznn4I3GSXqqqglLpSVzgbDn2us9VYgfbSdUbB_4Af5FfUj_aPsFedkc7OzvSIPSOkg3vevYxjBtGWL2hdds3r9AJbXtWUdKxo8Pc1sfoLKU7UqoRtOvEG3TM-0bUvKUn6Nc2-Ns_P39niBNOS1zdqkasbMFYh2mOsAOf3Ao4R1B5Ap-x81jhWWW3B_cu77Ayq_IaDPawxADeBB2dhwLDPKo04WBx3kE58rrIpHN8ibVKgCPMIea36LVVY4Kz536Kvn_-9O3qS7X9en1zdbmtNCcsV6yzhvZDQ4RWltGac9CdYYIQDbXmxlhhFBXWEGNb6LQA2gtWyMMw2AY4P0UXT7rzMkxgdPEf1Sjn6CYVH2RQTv6_8W4nb8MqKW3aumn7ovDhWSGGHwukLO_CEn0xLTnldbHC2v2f6omlY0gpgj28oETug5NhlPvg5N_gCv_9v74O7JeY-CMiB5kz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3134600273</pqid></control><display><type>article</type><title>Long‑term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report</title><source>PubMed Central</source><creator>Zhao, Lei ; Cheng, Xin ; Zhao, Hongbin ; Zhao, Haifei ; Di, Wenyu ; Mei, Zhihong</creator><creatorcontrib>Zhao, Lei ; Cheng, Xin ; Zhao, Hongbin ; Zhao, Haifei ; Di, Wenyu ; Mei, Zhihong</creatorcontrib><description>Neuroendocrine neoplasms of the pancreas (pNENs) are rare. In February 2021, a 54-year-old woman was diagnosed with pNEN and multiple metastases within the liver. The patient, diagnosed with grade G2 neuroendocrine neoplasm (T4N0M1), underwent an ultrasonography-guided liver biopsy and radiofrequency ablation. After receiving Sandostatin LAR in April 2021, side effects led to its discontinuation after seven cycles. Following two sessions of radiofrequency ablation, the patient's condition was stable. However, disease progression was noted in September 2023, resulting in hemodialysis and closed peritoneal drainage. Surufatinib was administered, stabilizing the tumor by November 2023. The patient underwent transarterial chemoembolization due to a large tumor burden, with subsequent MRCP showing stability from diagnosis in February 2021 to June 2024. The present case report highlights the role of tailored treatment strategies considering patient comorbidities and tumor biology, and the significance of secondary puncture biopsy, which, despite not being pursued by the patient in the present study due to the associated risks, may provide survival benefits for patients with advanced or metastatic pNEN.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2024.14795</identifier><identifier>PMID: 39564371</identifier><language>eng</language><publisher>Greece: Spandidos Publications UK Ltd</publisher><subject>Abdomen ; Biopsy ; Biotechnology ; Case Report ; Case reports ; Chemotherapy ; Hospitals ; Liver ; Medical prognosis ; Metastasis ; Pancreas ; Pathology ; Patients ; Tumors ; Ultrasonic imaging</subject><ispartof>Oncology letters, 2025-01, Vol.29 (1), p.49, Article 49</ispartof><rights>Copyright: © 2024 Zhao et al.</rights><rights>Copyright Spandidos Publications UK Ltd. 2025</rights><rights>Copyright: © 2024 Zhao et al. 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c302t-28fd19b506caf21433ec8d2600ce4c3ddf6da16fd0df7e8c6e19626cabbbf5e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574579/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574579/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39564371$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Lei</creatorcontrib><creatorcontrib>Cheng, Xin</creatorcontrib><creatorcontrib>Zhao, Hongbin</creatorcontrib><creatorcontrib>Zhao, Haifei</creatorcontrib><creatorcontrib>Di, Wenyu</creatorcontrib><creatorcontrib>Mei, Zhihong</creatorcontrib><title>Long‑term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Neuroendocrine neoplasms of the pancreas (pNENs) are rare. In February 2021, a 54-year-old woman was diagnosed with pNEN and multiple metastases within the liver. The patient, diagnosed with grade G2 neuroendocrine neoplasm (T4N0M1), underwent an ultrasonography-guided liver biopsy and radiofrequency ablation. After receiving Sandostatin LAR in April 2021, side effects led to its discontinuation after seven cycles. Following two sessions of radiofrequency ablation, the patient's condition was stable. However, disease progression was noted in September 2023, resulting in hemodialysis and closed peritoneal drainage. Surufatinib was administered, stabilizing the tumor by November 2023. The patient underwent transarterial chemoembolization due to a large tumor burden, with subsequent MRCP showing stability from diagnosis in February 2021 to June 2024. The present case report highlights the role of tailored treatment strategies considering patient comorbidities and tumor biology, and the significance of secondary puncture biopsy, which, despite not being pursued by the patient in the present study due to the associated risks, may provide survival benefits for patients with advanced or metastatic pNEN.</description><subject>Abdomen</subject><subject>Biopsy</subject><subject>Biotechnology</subject><subject>Case Report</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Hospitals</subject><subject>Liver</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Pancreas</subject><subject>Pathology</subject><subject>Patients</subject><subject>Tumors</subject><subject>Ultrasonic imaging</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpVUU1v1TAQtFARrUqPXJElznn4I3GSXqqqglLpSVzgbDn2us9VYgfbSdUbB_4Af5FfUj_aPsFedkc7OzvSIPSOkg3vevYxjBtGWL2hdds3r9AJbXtWUdKxo8Pc1sfoLKU7UqoRtOvEG3TM-0bUvKUn6Nc2-Ns_P39niBNOS1zdqkasbMFYh2mOsAOf3Ao4R1B5Ap-x81jhWWW3B_cu77Ayq_IaDPawxADeBB2dhwLDPKo04WBx3kE58rrIpHN8ibVKgCPMIea36LVVY4Kz536Kvn_-9O3qS7X9en1zdbmtNCcsV6yzhvZDQ4RWltGac9CdYYIQDbXmxlhhFBXWEGNb6LQA2gtWyMMw2AY4P0UXT7rzMkxgdPEf1Sjn6CYVH2RQTv6_8W4nb8MqKW3aumn7ovDhWSGGHwukLO_CEn0xLTnldbHC2v2f6omlY0gpgj28oETug5NhlPvg5N_gCv_9v74O7JeY-CMiB5kz</recordid><startdate>20250101</startdate><enddate>20250101</enddate><creator>Zhao, Lei</creator><creator>Cheng, Xin</creator><creator>Zhao, Hongbin</creator><creator>Zhao, Haifei</creator><creator>Di, Wenyu</creator><creator>Mei, Zhihong</creator><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20250101</creationdate><title>Long‑term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report</title><author>Zhao, Lei ; Cheng, Xin ; Zhao, Hongbin ; Zhao, Haifei ; Di, Wenyu ; Mei, Zhihong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c302t-28fd19b506caf21433ec8d2600ce4c3ddf6da16fd0df7e8c6e19626cabbbf5e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Abdomen</topic><topic>Biopsy</topic><topic>Biotechnology</topic><topic>Case Report</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Hospitals</topic><topic>Liver</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Pancreas</topic><topic>Pathology</topic><topic>Patients</topic><topic>Tumors</topic><topic>Ultrasonic imaging</topic><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Lei</creatorcontrib><creatorcontrib>Cheng, Xin</creatorcontrib><creatorcontrib>Zhao, Hongbin</creatorcontrib><creatorcontrib>Zhao, Haifei</creatorcontrib><creatorcontrib>Di, Wenyu</creatorcontrib><creatorcontrib>Mei, Zhihong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Lei</au><au>Cheng, Xin</au><au>Zhao, Hongbin</au><au>Zhao, Haifei</au><au>Di, Wenyu</au><au>Mei, Zhihong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long‑term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2025-01-01</date><risdate>2025</risdate><volume>29</volume><issue>1</issue><spage>49</spage><pages>49-</pages><artnum>49</artnum><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Neuroendocrine neoplasms of the pancreas (pNENs) are rare. In February 2021, a 54-year-old woman was diagnosed with pNEN and multiple metastases within the liver. The patient, diagnosed with grade G2 neuroendocrine neoplasm (T4N0M1), underwent an ultrasonography-guided liver biopsy and radiofrequency ablation. After receiving Sandostatin LAR in April 2021, side effects led to its discontinuation after seven cycles. Following two sessions of radiofrequency ablation, the patient's condition was stable. However, disease progression was noted in September 2023, resulting in hemodialysis and closed peritoneal drainage. Surufatinib was administered, stabilizing the tumor by November 2023. The patient underwent transarterial chemoembolization due to a large tumor burden, with subsequent MRCP showing stability from diagnosis in February 2021 to June 2024. The present case report highlights the role of tailored treatment strategies considering patient comorbidities and tumor biology, and the significance of secondary puncture biopsy, which, despite not being pursued by the patient in the present study due to the associated risks, may provide survival benefits for patients with advanced or metastatic pNEN.</abstract><cop>Greece</cop><pub>Spandidos Publications UK Ltd</pub><pmid>39564371</pmid><doi>10.3892/ol.2024.14795</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2025-01, Vol.29 (1), p.49, Article 49 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11574579 |
| source | PubMed Central |
| subjects | Abdomen Biopsy Biotechnology Case Report Case reports Chemotherapy Hospitals Liver Medical prognosis Metastasis Pancreas Pathology Patients Tumors Ultrasonic imaging |
| title | Long‑term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T18%3A23%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%E2%80%91term%20survival%20after%20comprehensive%20treatment%20in%20a%20patient%20with%20advanced%20neuroendocrine%20neoplasm%20of%20the%20pancreas:%20A%20case%20report&rft.jtitle=Oncology%20letters&rft.au=Zhao,%20Lei&rft.date=2025-01-01&rft.volume=29&rft.issue=1&rft.spage=49&rft.pages=49-&rft.artnum=49&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2024.14795&rft_dat=%3Cproquest_pubme%3E3134600273%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3134600273&rft_id=info:pmid/39564371&rfr_iscdi=true |